Considering the overall implications of mTOR signaling in mediating IFN biological effects, it will be important to determine whether, in treatment-naïve melanoma patients, a high- or low intratumoral activity of mTORC1 or mTORC2 could help predict the therapeutic response to ICI. The gene discussed is IFNA1; the disease is melanoma.